How has been the historical performance of Eiko Lifescience?

Answer:The historical performance of Eiko Lifescience shows significant growth over the years, particularly from March 2018 to March 2025.

Breakdown:
Eiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trend in total operating income, which rose from 2.34 Cr to 37.66 Cr during the same period. The company's total expenditure also grew, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, primarily driven by rising raw material costs. Operating profit, which was 0.35 Cr in March 2018, turned negative in March 2020 at -4.50 Cr but rebounded to 3.48 Cr by March 2025. This recovery is mirrored in the profit before tax, which improved from 0.25 Cr in March 2018 to 2.92 Cr in March 2025, after experiencing losses in the intervening years. The profit after tax followed a similar trajectory, moving from 0.20 Cr in March 2018 to 2.18 Cr in March 2025. The company's total assets increased significantly from 10.95 Cr in March 2018 to 66.10 Cr in March 2025, while total liabilities also rose, from 10.95 Cr to 66.10 Cr. Cash flow from operating activities turned positive at 2.00 Cr in March 2025, contributing to a closing cash balance of 11.00 Cr, up from 0.00 Cr in previous years. Overall, Eiko Lifescience has shown a remarkable recovery and growth in its financial performance over the years.